(NYSEMKT: STXS) Stereotaxis's forecast annual revenue growth rate of 42.11% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 3.89%, and it is also forecast to beat the US market's average forecast revenue growth rate of 19.3%.
Stereotaxis's revenue in 2026 is $30,067,000.On average, 6 Wall Street analysts forecast STXS's revenue for 2026 to be $4,026,925,129, with the lowest STXS revenue forecast at $3,682,430,042, and the highest STXS revenue forecast at $4,219,012,705. On average, 7 Wall Street analysts forecast STXS's revenue for 2027 to be $5,427,150,365, with the lowest STXS revenue forecast at $4,713,510,453, and the highest STXS revenue forecast at $6,249,609,842.
In 2027, STXS is forecast to generate $5,445,086,555 in revenue, with the lowest revenue forecast at $4,713,510,453 and the highest revenue forecast at $6,007,621,582.